GW26-e4626 Percutaneous transluminal coil embolization of septal artery for ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy  by Jiang, Qingan et al.
J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 6 , S U P P L S , 2 0 1 5 C221associated genes have been identiﬁed, including the gene encoding car-
diac troponin T type-2 (TNNT2). We examined polymorphisms of the
TNNT2 gene in a Kazak family from Xinjiang, China, and in idiopathic
DCM (IDCM) patients of both Kazak and Han ethnicity.
METHODS Peripheral blood samples were collected from 9 members
of the FDCM, from 180 patients with IDCM (90 Kazak and 90 Han), and
180 healthy controls (90 Kazak and 90 Han). PCR was used to amplify
15 exons and nearby introns of the TNNT2 gene. The ampliﬁed prod-
ucts were sequenced and compared to the standard sequence in
Pubmed by BLAST and CHROMAS software, to identify mutation sites.
RESULTS IDCM from Kazak and Han were complied for Hardy-Weinberg
equilibrium. There was a signiﬁcant difference in the genotype distribu-
tion (c2 ¼6.67, P ¼0.015) and allele frequency (c2 ¼5.17, P ¼0.0017) be-
tween Kazaks with IDCM and Kazak controls of SNP rs3729547.
Meanwhile, it also has a difference in the genotype distribution (c2 ¼7.62,
P ¼0.022) and allele frequency (c2 ¼6.73, P ¼0.009) between Han with
IDCM and Han controls, but the rate of IDCM was descend. A novel
variant (c.617G > T) was identiﬁed in one FDCM patient at exon 13, this
mutation caused an amino acid substitution.
CONCLUSIONS The TNNT2 SNP rs3729547 is not only a possible in-
dependent risk factor for Han ethnicity, but also for Kazak ethnicity.
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Treatment for hypertrophic obstructive cardiomyopathy by coil
embolization of a targeted septal artery
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OBJECTIVES To investigate the immediate and short-term thera-
peutic efﬁcacy and feasibility of coil embolization of a targeted septal
artery in patients with hypertrophic obstructive cardiomyopathy
(HOCM).
METHODS Four patients with hypertrophic obstructive cardiomyop-
athy refractory to medication were chosen, and treated with coil
embolization of a targeted septal artery. Preoperative, intraoperative
and postoperative left ventricular outﬂow tract pressure gradient
(LVOTPG), septal thickness and systolic anterior motion of mitral
(SAM) phenomenon were compared. Postoperative complications and
improvement of clinical symptoms were observed.
RESULTS Embolization of the targeted septal branch was successfully
performed in 4 patients. Compared with preoperative LVOTPG of
patients after balloon pressure and complete occlusion were signiﬁ-
cantly lower(92.5026.30 vs. 38.006.93 and 28.256.24 mmHg;
P <0.05, respectively). The average septal thickness of patients at one
month after operation was not statistically signiﬁcant difference
compared with the preoperative value(18.402.36 vs. 18.682.42 mm;
P >0.05, respectively). Follow-up of the 4 cases at 1 month after
operation revealed remarkable attenuation of SAM phenomenon. We
did not detect ventricular tachycardia and atrioventricular block.
Postoperative NYHA classiﬁcation were signiﬁcantly lower than
baseline (3.000.82 vs. 1.500.58; P <0.05, respectively).
CONCLUSIONS The study showed treatment for hypertrophic obstruc-
tive cardiomyopathy by coil embolization of a targeted septal artery is
feasible.In the treatment of HOCM, coil embolization of a targeted septal
artery can signiﬁcantly reduce LVOTPG and improve clinical symptoms.
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OBJECTIVES Recent studies have shown that smoking and drinking
are associated with poorer outcomes in patients with cardiomyopa-
thy. The purpose of this study was to determine all-cause mortality in
dilated cardiomyopathy (DCM) associated with smoking and drinking.METHODS An observational cohort study was undertaken in DCM pa-
tients from November 2003 to September 2011. A total of 1118 patients
were enrolled, with a mean follow-up of 3.52.3 years. Standard de-
mographics were obtained, and transthoracic echocardiography and
routine blood testing were performed shortly after admission. Outcome
assessment was based on the all-cause death after admission.
RESULTS The patients were divided into three groups: non-smokers
(n ¼593), mild to moderate smokers (n ¼159) and heavy smokers
(n ¼366). The all-cause mortality rates showed no differences between
the three groups (23.8%, 20.8% and 24%, respectively; log-rank c2 ¼1.281,
P ¼0.527). There was also no signiﬁcant difference in mortality between
non-drinkers (n ¼747), mild drinkers (n ¼142) and moderate drinkers
(n ¼229) (23.7%, 23.2% and 22.3%, respectively; log-rank c2 ¼2.343,
P ¼0.310). In the Cox analysis, neither the smoking (HR 0.971, P ¼0.663)
nor the drinking status (HR 0.891, P ¼0.140) was a signiﬁcant indepen-
dent predictor of all-cause mortality in patients with DCM.
CONCLUSIONS In conclusion, there were no signiﬁcant differences in
mortality between the smoking- and drinking-related patient groups,
indicating no effect of smoking and drinking on all-cause mortality in
patients with DCM in the present large-scale study.
GW26-e0787
Correlation between Tei index and B-natriuretic peptide in dilated
cardiomyopathy patients
Xuewei Chang,1 Shouyan Zhang,1 Yajuan Fan,2 Yidong Wei,3
Jinghan Wei4
1Department of Cardiology, Luoyang Central Hospital, afﬁliated to
Zhengzhou University; 2Department of Ultrasound, Luoyang Central
Hospital, afﬁliated to Zhengzhou University; 3Department of
Cardiology, Shanghai Tenth People’s Hospital, afﬁliated to tongji
University; 4Department of Cardiology, The ﬁrst afﬁliated hospital of
Zhengzhou University
OBJECTIVES The growing number of heart failure patients is becoming
an important issue in cardiology. B-natriuretic peptide (BNP) is a recog-
nized marker of heart failure, including in patients with dilated cardio-
myopathy. The Tei index is an indicator of left ventricular function. The
aim of the study was to evaluate the relationship between Tei index and
the concentration of plasma BNP in dilated cardiomyopathy patients.
METHODS Fifty patients with dilated cardiomyopathy were enrolled
in the study. Fifty healthy individuals were assigned to the control
group. BNP was measured by enzyme linked immunosorbent assay
(ELISA). Echocardiography was performed to calculate Tei index.
RESULTS Median value of BNP in patients with dilated cardiomyop-
athy was 1086.1 pg/ml, and 42.8 pg/ml in control group (p < 0.05). The
median value of the Tei index was 0.80 in patients with dilated car-
diomyopathy, 0.30 in individuals with control group. LVEDD, LVESD
were signiﬁcantly higher in dilated cardiomyopathy patients also. All
the differences were statistically signiﬁcant (p < 0.05). A signiﬁcant
positive correlation (R¼0.401, p < 0.05) between BNP and the TEI
index was found. The stepwise regression analysis showed closer
relationship existing in Tei index and BNP.
CONCLUSIONS Tei index, BNP was signiﬁcantly increased in dilated
cardiomyopathy patients. There was a signiﬁcant positive correlation
between them. Tei index was a better index to estimate ventricular
global function than other conventional indices.
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OBJECTIVES To evaluate the feasibility and the safety after non-
surgical septal myocardial reduction by coil embolization in hyper-
trophic obstructive cardiomyopathy (HOCM).
METHODS Thirteen patients (pts) (male: 5 pts; mean age: 48 (10 years)
with HOCM and drug-refractory symptoms underwent ablation of
septal hypertrophy by coil embolization with detachable coils. The
Tornado coils (Cook Inc, Bloomington, IN, USA), 3 or 4mm in diam-
eter and 2 or 3cm in length, were delivered through a 3F RenegadeTM
Hi-Flo microcatheter (Boston Scientiﬁc Scimed, Maple Grove, MN,
USA) positioned inside the target vessel as distally as possible. One or
more straight coils were used for each target vessel until complete
ﬂow obstruction was noted. The intraventricular pressure gradient
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occlusion was ﬁnally documented by coronary angiography.
RESULTS All patients were symptomatic (NYHA class 3 or 4). The target
septal vessels were successfully occluded in all patients, without com-
plications. The embolized septal branches: 1 vessel in 8 patients; 2 vessels
in 5 patients. The number of coils delivered ranged from 1to 3 / patient.
Moderate pain was recorded during and after the procedure and the cTnI
level increased four- to nine-fold. The pressure gradient diminished
during the procedure from 82  2.3 mm Hg to 27 15 mm Hg. Trans-
thoracic echocardiography showed a signiﬁcant reduction of the inter-
ventricular septum thickness and left ventricular outﬂow tract gradient
(23  3 vs. 15 2 mm, P ¼ 0.0001; 79  2.3 to 33  14mmHg, P ¼0.0001,
respectively) at 6 month-follow-up. Clinical improvement was recorded
in all patients compared with baseline (NYHA class 1 or 2), and all patients
were neither detected severe ventricular arrhythmia nor permanent
atrioventricular blockage following the procedure.Three patients pre-
sented permanent bundle branch block.
CONCLUSIONS Percutaneous transluminal coil embolization is an efﬁ-
cient and safe approach for transcatheter ablation of septal hypertrophy in
HOCM. This technique induced myocardial necrosis without the toxic
effects of alcohol septal ablation and surgical myocardial septal reduction.
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OBJECTIVES From the pedigrees of families with or without muta-
tions in beta-myosin heavy chain gene (MYH7) afﬂicted in two or more
generations with hypertrophic cardiomyopathy (HCM), age and
maximal wall thickness (MWT) of left ventricle at diagnoses were
evaluated to investigate the patterns of inheritance.
METHODS 56 individuals were analyzed from 25 families. Linear
mixed effects models were adopted to prevent misinterpretation due
to the cohort effect. Publication data contain 9 sarcomere mutations
(181 individuals in 52 families) were also extracted.
RESULTS MYH7 mutations were detected in 9 of the 25 probands, The
median age of HCM diagnosis was 24 in younger generation and 55 in
older (p < 0.001). In the parametric model, the estimated change in the
expected age at diagnosis for the entire cohort was 25.8 years (p < 0.001).
Statistically signiﬁcant earlier ages at diagnosis were also observed within
subgroups of MYH7þ and MYH7- mutations, proband over and below 30
years old families. Although the estimated change in MWT at diagnosis
for the entire cohort was only 2.161 mm (p ¼ 0.212), proband below 30
years subgroup got 10.393 mm (p ¼ 0.018) thicker in younger generation
in MWT, and showed a signiﬁcant reversed correlation with age. Analysis
of publication data also supports above ﬁnding.
CONCLUSIONS Familial HCM prone to be diagnosed at an earlier age in
later generations. Patients who are younger with relative contract to HCM,
especially those who be diagnosed earlier than 30 should continue to be
tracked to offer appropriate screening modalities as earlier as possible.
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OBJECTIVES To investigate the effect and safety of recombinant
human brain natriuretic peptide(rhBNP) on heart failure in acute se-
vere viral myocarditis patients(ASVMC).
METHODS 27 patients from Jan 2010 to Dec 2013 admitted to the Third
Afﬁliated Hospital of Sun Yat-Sen University were divided into two
group, rhBNP group 14 patients, control group 13 patients, rhBNP
group received rhBNP on the treatment of cedilanid, diuresis, vascular
dilation, BNP, cTnI, CK-MB and echocardiography were observed,
therapeutic effect of two group were also observed.
RESULTS rhBNP decreased BNP [(203.139.8)vs.( 1185.548.3) pg/
ml], cTnT [(13.59.8)vs. (24.813.2) mg/L], CK-MB[(32.910.7)
vs.(195.348.2) U/L], improved LVEF [(59.29.2)% vs.( 38.18.8)%]
signiﬁcantly, P<0.05. Furthermore, the therapeutic effect of rhBNP
group were better than control group (92.8% vs.84.6%, P<0.05), and
we didn’t observe obvious side effects in rhBNP group.CONCLUSIONS rhBNP is an effective and safe therapeutic measures
for heart failure in ASVMC.
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OBJECTIVES To review the clinical features of fulminant myocartitis,
in order to provide assistance to the clinical management.
METHODS The clinic data of 183 patients with viral myocarditis,
including 153 cases of acute myocarditis and 30 cases of fulminant
myocarditis admitted in our hospital during January 2008 and Dec
2012 were retrospectively analyzed. The age of onset, interval after
virus infect, initial symptoms, auxiliary examination, treatment, and
turnover were compared in the study.
RESULTS The average onset age of fulminant myocarditis and acute
myocarditis were similar[(22.37.6) vs(26.212.6) years, P¼0.1055]. There
was a signiﬁcant difference between the two gourps in the rate of patients
with a explicit history of virus infection[30.0%(9/30)vs 78.4%(120/153),
c2¼28.3, P<0.001], the average interval after virus infect [(3.12.2)
vs(7.03.80) d, P<0.001] and the length of hospital stay[(12.16.9)
vs(6.94.50) d, P<0.001]. Chest congestion (101/153,66.0%), feeble-
ness(76/153,49.7%), ﬂuster(74/153,48.4%) are the most onset symptoms of
acute myocarditis, while chest congestion (24/30,80.0%), shortness of
breath(14/30,46.7%), feebleness(13/30,43.3%) in ﬂunimant myocarditis.
Advanced A-V block(19/30,63.3%), cardiogenic shock(18/30 ,60.0%), ven-
tricular arrhythmia(16/30,53.3%), Adams-Stokes syndrome(8/30,26.67%)
and acute renal failure(8/30,26.7%) were the most complications of ﬂu-
nimant myocarditis. Temporary pacemaker(11 cases), extracorporeal
membrane exygenator(7 cases) and intra-aortic balloon pump(7 cases)
were applied in critical patients. In acute phase, 21 cases were cured, 9
cases was dead of cardiogenic shock and ventricular(27,30.0%). Two dead
cases applied with ECMO because of delay. These dead cases were died
within one week after be in hospital. Low ventricular ejection
fraction(P¼0.032), cardiogenic shock(P¼0.004), and mechanical ven-
tilation(P¼0.001) were relatived with dead of fulminant myocarditis in
acute phase. Three cases with low left ventricular ejection
fraction(EF<50%) who reviewed the echocardiography was normal one
month later. Besides 11 cases with ST-T wave imitated myocardiac
infarction was normal one month later. In follow-up of 21 cases fulminant
myocarditis, their heart functions were recovered(NYHA I), and 2 cases
relapsed, while 2 cases relapsed in the follow-up of 50 cases of acute
myocarditis. The relapsed cases all diagnosed with acute myocarditis, and
cured by nutritional supportive therapy. There is no signiﬁcant difference
between 2 groups(P¼0.357).
CONCLUSIONS The fulminant myocarditis has a rapid onset, most of
which has no prodrome of virus infection or a shorter interval than acute
myocarditis. Timely and effectivemechanical circulatory support is critical
for fulminant myocarditis. The prognosis of fulminant myocarditis is
favorable, and these is no difference compared with acute myocarditis.
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OBJECTIVES To explore the echocardiographic feature and prognosis
of cardiac amyloidosis due to multiple myeloma.
METHODS Patients with cardiac involvement of light-chain type
amyloidosis due to multiple myeloma conﬁrmed by pathology were
enrolled and echocardiographic data were analyzed retrospectively.
RESULTS Seven patients were identiﬁed (ﬁve man and two woman) be-
tween 1998 and 2015. Mean age at diagnosis was 53.19 5. 9 (49-59) years.
All patients presented cardiac manifestations (heart failure n¼6, rhythm
disorders n¼1) and extra-cardiac manifestations (renal n¼6, gastrointes-
tinal n¼5). Echocardiography demonstrated: Symmetrically increased LV
wall thickness in seven patients, one with normal size of LV cavity and six
with small LV cavity. Five patients showed small pericardial effusions.
Five patients with granular speckled appearance and two patients with
diffuse sparkling appearance．E/A ¼ 0.710.22, EF ¼ 52.116.2%. All pa-
tients with cardiac failure at diagnosis (n¼6) died with a median survival
of 1.5 month duration.
CONCLUSIONS Cardiac involvement is rare but crucial in patients’
prognosis with multiple myeloma. The typical echocardiographic ap-
pearances would be enough to diagnose cardiac amyloidosis, if an addi-
tional histological specimen from another tissue conﬁrms amyloidosis.
